Non-Small Cell Lung Cancer (NSCLC)

The agency places a partial clinical hold on the phase 3 PRESERVE-003 trial due to varying results between the squamous and nonsquamous NSCLC cohorts.

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.

Patients with non–small cell lung cancer and larger brain metastases may benefit most from the addition of up-front stereotactic radiosurgery to TKIs.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Data from the LUMINOSITY trial support the application for telisotuzumab vedotin in nonsquamous NSCLC harboring c-Met protein overexpression.

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.

The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.

Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.

Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.

Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.

The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.

Phase 2 data show meaningful efficacy with taletrectinib regardless of whether patients with ROS1-positive NSCLC previously received tyrosine kinase inhibitors.

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial in late 2024.

Confirmed partial responses with firmonertinib occurred across a range of EGFR PACC mutations among patients with NSCLC in the phase 1b FURTHER trial.

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.

Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.

BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

Amivantamab/lazertinib also reduces the risk of second progression or death compared with osimertinib in the phase 3 MARIPOSA trial.

Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.